Previous 10 | Next 10 |
Shares of Alimera Sciences Inc. (NASDAQ:ALIM) traded at a new 52-week high today of $13.50. Approximately 28.5 million shares have changed hands today, as compared to an average 30-day volume of 33,000 shares. Alimera Sciences Inc. (NASDAQ:ALIM) defies analysts with a current price ($6.0...
ATLANTA, April 06, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced ...
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
ATLANTA, March 02, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces t...
Alimera Sciences, Inc (ALIM) Q4 2021 Earnings Conference Call February 24, 2022, 9:00 AM ET Company Participants Scott Gordon – CORE IR Richard Eiswirth – President, CEO & Director Philip Jones – CFO Conference Call Participants Alexander Nowak – Craig-Hallum Y...
Alimera Sciences press release (NASDAQ:ALIM): Q4 GAAP EPS of -$0.59 misses by $0.17. Revenue of $13.95M (+1.3% Y/Y) beats by $0.55M. For further details see: Alimera Sciences GAAP EPS of -$0.59 misses by $0.17, revenue of $13.95M beats by $0.55M
Fourth Quarter Highlights: Consolidated Net Revenue of $14 Million Up 15% vs. Third Quarter of 2021; Up 1% vs. Fourth Quarter of 2020 Full Year 2021 Highlights: Consolidated Net Revenue of $59 Million Up 16% vs 2020 Consolidated Net ...
Alimera Sciences (NASDAQ:ALIM) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is -$0.28 and the consensus Revenue Estimate is $13.4M (-2.7% Y/Y). For further details see: Alimera Sciences Q4 2021 Earnings Preview ...
Alimera Sciences (NASDAQ:ALIM) reported three-year results of a study called PALADIN evaluating the ILUVIEN implant in patients with diabetic macular edema (DME), an eye complication in people with diabetes. The results, which were published in the journal Ophthalmology, showed...
Best corrected visual acuity and central subfield thickness were significantly improved at 36 months ILUVIEN treatment resulted in a 70.5% reduction in treatment burden Results confirm that use of prior corticosteroid per the U.S. label mitigates the ri...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
2024-07-07 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 11:30:02 ET Alliance Global Partners analyst issues NEUTRAL recommendation for ALIM on June 25, 2024 10:23AM ET. The previous analyst recommendation was Buy. ALIM was trading at $5.53 at issue of the analyst recommendation. The overall analyst consensus : HOLD...
2024-06-25 07:00:05 ET Yi Chen from H.C. Wainwright issued a price target of $6.00 for ALIM on 2024-06-25 06:08:00. The adjusted price target was set to $6.00. At the time of the announcement, ALIM was trading at $5.54. The overall price target consensus is at $7.25 with...